Cargando…
Neoplasm Risk in Rheumatic Diseases Has No Correlation With Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs Usage—A Population-Based Nested Case–Control Study
Objectives: To investigate whether there is an elevated neoplasm risk in patients with rheumatic diseases treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Methods: A population-based nested case–control study was performed by retrieving all patients newly diagnos...
Autores principales: | Cai, Shaozhe, Perng, Wuu-Tsun, Huang, Jing Y., Chiou, Jeng-Yuan, Dong, Lingli, Wei, James C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479172/ https://www.ncbi.nlm.nih.gov/pubmed/32984368 http://dx.doi.org/10.3389/fmed.2020.00473 |
Ejemplares similares
-
Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021) -
Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees
por: Tsakas, James J., et al.
Publicado: (2022) -
IL-33 in Rheumatic Diseases
por: Dong, Yuanji, et al.
Publicado: (2021) -
Editorial: Rheumatic Diseases and Infection
por: Dong, Lingli, et al.
Publicado: (2022) -
Rheumatic diseases, rheumatism and arthritis
por: Brugsch, Heinrich Georg, 1903-
Publicado: (1957)